2024
Disability and Recurrent Stroke Among Participants in Stroke Prevention Trials
de Havenon A, Viscoli C, Kleindorfer D, Sucharew H, Delic A, Becker C, Robinson D, Yaghi S, Li V, Lansberg M, Cramer S, Mistry E, Sarpong D, Kasner S, Kernan W, Sheth K. Disability and Recurrent Stroke Among Participants in Stroke Prevention Trials. JAMA Network Open 2024, 7: e2423677. PMID: 39028666, PMCID: PMC11259901, DOI: 10.1001/jamanetworkopen.2024.23677.Peer-Reviewed Original ResearchMeSH KeywordsAgedCohort StudiesDisability EvaluationDisabled PersonsFemaleHumansMaleMiddle AgedRecurrenceSecondary PreventionStrokeConceptsPrevention trialsPoststroke disabilityRecurrent stroke ratesRecurrent strokeCohort studyRate of recurrent strokeStroke Prevention TrialIncreased hazardInsulin Resistance InterventionSecondary prevention trialsBaseline disabilityAssociated with increased ratesStroke rateMain OutcomesFunctional statusResistance InterventionStudy baselineSecondary outcomesPrimary outcomeWorsening heart failureModified Rankin ScaleProfession's participationLong-term followVascular deathDisabilitySecondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts
Rivier C, Acosta J, Leasure A, Forman R, Sharma R, de Havenon A, Spatz E, Inzucchi S, Kernan W, Falcone G, Sheth K. Secondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts. Journal Of The American Heart Association 2024, 13: e033322. PMID: 38639369, PMCID: PMC11179946, DOI: 10.1161/jaha.123.033322.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntihypertensive AgentsBlood PressureCross-Sectional StudiesFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPractice Guidelines as TopicRisk AssessmentRisk FactorsSecondary PreventionStrokeUnited KingdomUnited StatesConceptsMyocardial infarctionPrevention scoreSecondary preventionImplementation of preventive therapyNational cohortUK BiobankAntiplatelet therapy useGuideline-directed therapyPrevention profilesBlood pressure controlAdherence to guideline-directed therapyLow-density lipoprotein controlNeighborhood deprivation levelHistory of strokeVascular risk profileStatin useAntiplatelet useTherapy usePreventive therapyComparison to participantsPrevention criteriaCross-sectional analysisBlood pressurePatientsPressure control
2023
Disability Status and Secondary Prevention Among Survivors of Stroke: A Cross‐Sectional Analysis of the 2011 to 2018 National Health and Nutrition Examination Survey
Zhou T, de Havenon A, Sheth K, Ross J. Disability Status and Secondary Prevention Among Survivors of Stroke: A Cross‐Sectional Analysis of the 2011 to 2018 National Health and Nutrition Examination Survey. Journal Of The American Heart Association 2023, 12: e030869. PMID: 38014672, PMCID: PMC10727323, DOI: 10.1161/jaha.123.030869.Peer-Reviewed Original ResearchSecondary Ischemic Stroke Prevention
Bangad A, Abbasi M, de Havenon A. Secondary Ischemic Stroke Prevention. Neurotherapeutics 2023, 20: 721-731. PMID: 36877331, PMCID: PMC10275832, DOI: 10.1007/s13311-023-01352-w.Peer-Reviewed Original ResearchConceptsSecondary ischemic stroke preventionIschemic stroke preventionRecurrent ischemic strokeStroke preventionIschemic strokeRisk factorsMajor public health concernSecondary stroke preventionLifestyle risk factorsVascular risk factorsRecurrent stroke riskAvailability of treatmentPublic health concernHealth care systemAHA guidelinesStroke riskSurgical treatmentHealth burdenPatient burdenFirst strokeStrokeHealth concernCare systemPreventionTreatment
2022
Cost‐Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke
Zhou LW, Kraler L, de Havenon A, Lansberg MG. Cost‐Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke. Journal Of The American Heart Association 2022, 11: e024992. PMID: 35656996, PMCID: PMC9238703, DOI: 10.1161/jaha.121.024992.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsHealth care costsHigher quality-adjusted life yearsNet monetary benefitLifetime quality-adjusted life yearsProbabilistic sensitivity analysesCare costsMonetary benefitsSensitivity analysisLife yearsCost inputsLifetime costsLower health care costsCost savingsCostBest available dataWillingnessSavingsMonte Carlo simulationsTreatment effectsCarlo simulationsAvailable dataBenefitsDecision tree
2021
Cilostazol for Secondary Stroke Prevention
de Havenon A, Sheth KN, Madsen TE, Johnston KC, Turan TN, Toyoda K, Elm JJ, Wardlaw JM, Johnston SC, Williams OA, Shoamanesh A, Lansberg MG. Cilostazol for Secondary Stroke Prevention. Stroke 2021, 52: e635-e645. PMID: 34517768, PMCID: PMC8478840, DOI: 10.1161/strokeaha.121.035002.Peer-Reviewed Original ResearchMeSH KeywordsCilostazolEvidence-Based MedicineHumansIschemic StrokePhosphodiesterase 3 InhibitorsSecondary PreventionStrokeConceptsSecondary stroke preventionStroke preventionDouble-blind placebo-controlled randomized trialLargest secondary stroke prevention trialSecondary stroke prevention trialsPlacebo-controlled randomized trialStroke Prevention TrialTreatment of claudicationOpen-label designNoncardioembolic ischemic strokePeripheral arterial diseaseLong-term treatmentOnset of benefitDays of treatmentEuropean Medicines AgencyCognitive outcome dataMillions of patientsPremature trial terminationDrug discontinuationMajor bleedingGastrointestinal symptomsStroke recurrenceIschemic strokeNoncardioembolic strokeSecondary preventionEvaluation of Systolic Blood Pressure, Use of Aspirin and Clopidogrel, and Stroke Recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial
de Havenon A, Johnston SC, Easton JD, Kim AS, Sheth KN, Lansberg M, Tirschwell D, Mistry E, Yaghi S. Evaluation of Systolic Blood Pressure, Use of Aspirin and Clopidogrel, and Stroke Recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial. JAMA Network Open 2021, 4: e2112551. PMID: 34086033, PMCID: PMC8178708, DOI: 10.1001/jamanetworkopen.2021.12551.Peer-Reviewed Original ResearchConceptsBaseline systolic blood pressureDual antiplatelet therapySystolic blood pressureTransient ischemic attackMinor Ischemic Stroke (POINT) trialNew transient ischemic attackAcute ischemic strokeIschemic strokeIschemic stroke trialsStroke recurrenceHazard ratioBlood pressurePrimary outcomeStroke trialsElevated baseline systolic blood pressureFit Cox proportional hazards modelsHigher baseline systolic blood pressureElevated systolic blood pressureCox proportional hazards modelDays of randomizationFuture stroke riskIschemic stroke recurrenceUse of aspirinSubgroup of patientsProportional hazards modelIschaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study
Yaghi S, Henninger N, Giles JA, Guerrero C, Mistry E, Liberman AL, Asad D, Liu A, Nagy M, Kaushal A, Azher I, Mac Grory B, Fakhri H, Espaillat K, Pasupuleti H, Martin H, Tan J, Veerasamy M, Esenwa C, Cheng N, Moncrieffe K, Moeini-Naghani I, Siddu M, Scher E, Trivedi T, Furie KL, Keyrouz SG, Nouh A, de Havenon A, Khan M, Smith EE, Gurol ME. Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study. Journal Of Neurology Neurosurgery & Psychiatry 2021, 92: 1062-1067. PMID: 33903185, PMCID: PMC8448925, DOI: 10.1136/jnnp-2021-326166.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnticoagulantsAtrial FibrillationEmbolic StrokeFemaleHumansIschemic StrokeMaleRecurrenceRisk Reduction BehaviorSecondary PreventionConceptsRecurrent ischemic eventsSymptomatic intracranial hemorrhageIschemic strokeIschemic eventsAtrial fibrillationAnticoagulation therapyAcute cardioembolic strokeAnticoagulation-naïve patientsInitiation of anticoagulationStroke prevention measuresComprehensive stroke centerIschemic stroke patientsAcute ischemic strokeCox regression analysisSecondary prevention strategiesCox hazard modelSICH riskAnticoagulant therapyAnticoagulation statusStroke centersCardioembolic strokeAF patientsConsecutive patientsEarly recurrenceIntracranial hemorrhage